Overview:
Relapsed/refractory multiple myeloma (RRMM) continues to present significant challenges due to resistance to existing therapies, patient variability, and the rapid introduction of new options such as CAR-T cell therapies and bispecific antibodies. Deciding how best to sequence these innovative treatments is increasingly complex, especially as bispecific antibodies are being considered for use in earlier lines of therapy. Additional challenges include managing side effects like cytokine release syndrome (CRS) and making bispecific antibodies more tolerable for patients.
In this 90-minute Cases and Conversations™ symposium,
expert faculty will guide participants through interactive, case-based discussions, providing practical insights and facilitating knowledge-sharing among oncology professionals. Delivering the program as a live webcast ensures broad accessibility and timely dissemination of practice-changing information on RRMM management.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Analyze efficacy and safety data from pivotal trials evaluating new and emerging therapies for relapsed/refractory multiple myeloma (R/R MM)
- Balance disease- and patient-specific factors to formulate individualized treatment plans for patients with early relapsed MM
- Incorporate evidence-based strategies to select and sequence T-cell therapies for heavily pretreated patients with R/R MM
- Implement proactive measures to mitigate treatment-related toxicities in patients with R/R MM
Dr. C. Ola Landgren, MD, PhD
Professor of Medicine, University of Miami
Chief, Division of Myeloma & Myeloma Institute
Paul J. DiMare Endowed Chair in Immunotherapy
Chief, Riney Family Multiple Myeloma Research Program
Co-Director, Translational and Clinical Oncology Program
Sylvester Comprehensive Cancer Center
Professor of Medicine
University of Miami Leonard M. Miller School of Medicine
Miami, Florida
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Physicians' Education Resource is proud to partner with The International Academy for Clinical Hematology (IACH)
